
Jared Gollob, MD, discusses phase 1b biomarker findings for KT-621, a STAT6 degrader in atopic dermatitis, presented at SID 2026.

Jared Gollob, MD, discusses phase 1b biomarker findings for KT-621, a STAT6 degrader in atopic dermatitis, presented at SID 2026.

The ongoing phase 2b BROADEN2 study will evaluate KT-621 across 3 dose levels in 200 patients over 16 weeks, with results expected to guide phase 3 dose selection.

Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics, spoke with Dermatology Times to discuss these trial results.